Results

1–10 of 197 results for Clinical Trial

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2024
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024
Silicone Oil Droplets in the Vitreous After Intravitreal Injection With a Silicone Oil-Free and a Siliconized Insulin Syringe: A Randomized Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2024
Fas Inhibition With ONL1204 for the Treatment of Geographic Atrophy: First-Time Results From a Phase 1b Study
Durga Borkar, MD
Annual Meeting Talks
2024
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Pooled Clinical Trial Safety Data of Neurotrophic Factorâ€“Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
Paul S. Bernstein, MD, PhD
Annual Meeting Talks
2024
Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024